Literature DB >> 35002786

Erratum: Augmented Liver Uptake of the Membrane Voltage Sensor Tetraphenylphosphonium Distinguishes Early Fibrosis in a Mouse Model.

.   

Abstract

[This corrects the article DOI: 10.3389/fphys.2021.676722.].
Copyright © 2021 Frontiers Production Office.

Entities:  

Keywords:  carbon tetrachloride; electron transport chain; liver fibrosis; liver voltage; membrane-voltage sensor; mitochondrial respiration; tetraphenylphosphonium (TPP)

Year:  2021        PMID: 35002786      PMCID: PMC8728887          DOI: 10.3389/fphys.2021.830151

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


Due to a production error, the following words were misspelled: “Fibro genic liver” in the Materials and Methods and Discussion sections should be “fibrogenic liver”; and “Fibro genesis” in the Materials and Methods section should be “fibrogenesis.” A correction has been made to the MATERIALS AND METHODS section, subsection Histopathology and Staging Fibrosis: “Liver fixed in 10% of phosphate-buffered formalin (Polysciences, Warrington, PA, USA) was dehydrated with graded ethanol, embedded in wax (Paraplast Plus; McCormick Scientific, Richmond, IL, USA), sliced at 5 μm, mounted on slides, and oven-dried, and deparaffinized and subjected to H and E staining as previously described (Ganapathy-Kanniappan et al., 2012). To detect collagen deposition, the liver sections were stained using Sirius Red stain (PolySciences Inc. Warrington, PA, USA) or Masson's trichrome stain (Sigma Aldrich, St. Louis, MO) as per the instructions of suppliers. Quantification of collagen staining was performed using ImageJ software (National Institutes of Health, Bethesda, US) (Schneider et al., 2012). Staging of the fibrosis was performed according to the METAVIR scoring system in which on a 5-point scale, F0 denotes no fibrosis (normal) and F4 refers to advanced cirrhosis (Poynard et al., 1997). Further experiments were performed using the control (F0) and early phase (F1) fibrogenic liver.” A correction has been made to the DISCUSSION section, first paragraph: “This study shows that the liver uptake of the membrane voltage sensor, 3H-TPP significantly increases in early fibrosis as confirmed by the onset of collagen deposition. Then, the upregulation of the OxPhos enzymes with a concomitant increase in mito-respiration in early fibrosis (F1) concurred with the augmented liver uptake of 3H-TPP. TPP has been implicated in the assessment pathophysiology of cancer (Min et al., 2004; Madar et al., 2007), cardiac disease (Higuchi et al., 2011; Gurm et al., 2012), and others, through the functional imaging modalities such as PET. However, its relevance in liver fibrosis/cirrhosis remains unknown, primarily due to the lack of any experimental study on the overall membrane voltage of the liver. Our findings provide the primary evidence that liver voltage may enable the detection of the fibrogenic liver at an early stage.” A correction has been made to the MATERIALS AND METHODS section, subsection Fibrogenesis by CCl4: “Animal experiments were performed as approved by the Institutional Animal Care and Use Committee. To establish the liver fibrosis model, 3–4 week old male C57BL/6 mice (15–20 g body weight) were procured from the Charles River Laboratories Inc. (Wilmington, MA, USA) and maintained in a temperature-controlled room with an alternating 12-h dark and light cycle. To determine the fibrotic stage, mice were randomly divided into control (vehicle, n = 7) and experimental groups (n = 7) representing 2, 4, and 6 weeks of CCl4 administration. Fibrogenesis was induced by intraperitoneal administration of 20% solution of CCl4 (Sigma Chemical Co., St. Louis, MO, USA) in olive oil (vehicle) (Mehendale et al., 1994; Wang et al., 2007; Jin et al., 2011; Karthikeyan et al., 2016), at a dose of 0.5 μl/g bodyweight every week thrice for up to 6 weeks. Histopathology and analysis of fibrosis markers were used to determine the early fibrotic stage.” The publisher apologizes for this mistake. The original version of this article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
  11 in total

1.  4-[18F]-tetraphenylphosphonium as a PET tracer for myocardial mitochondrial membrane potential.

Authors:  Gagandeep S Gurm; Stephan B Danik; Timothy M Shoup; Steven Weise; Kazue Takahashi; Shawna Laferrier; David R Elmaleh; Henry Gewirtz
Journal:  JACC Cardiovasc Imaging       Date:  2012-03

2.  Stable delineation of the ischemic area by the PET perfusion tracer 18F-fluorobenzyl triphenyl phosphonium after transient coronary occlusion.

Authors:  Takahiro Higuchi; Kenji Fukushima; Christoph Rischpler; Takuro Isoda; Mehrbod S Javadi; Hayden Ravert; Daniel P Holt; Robert F Dannals; Igal Madar; Frank M Bengel
Journal:  J Nucl Med       Date:  2011-05-13       Impact factor: 10.057

3.  NIH Image to ImageJ: 25 years of image analysis.

Authors:  Caroline A Schneider; Wayne S Rasband; Kevin W Eliceiri
Journal:  Nat Methods       Date:  2012-07       Impact factor: 28.547

4.  Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells.

Authors:  Zixue Jin; Rui Sun; Haiming Wei; Xiang Gao; Yongyan Chen; Zhigang Tian
Journal:  Hepatology       Date:  2010-12-07       Impact factor: 17.425

5.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

6.  Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Rani Kunjithapatham; Michael S Torbenson; Pramod P Rao; Kathryn A Carson; Manon Buijs; Mustafa Vali; Jean-François H Geschwind
Journal:  Radiology       Date:  2012-03       Impact factor: 11.105

7.  Tetraphenylphosphonium as a novel molecular probe for imaging tumors.

Authors:  Jung-Jun Min; Sandip Biswal; Christophe Deroose; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

8.  Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation.

Authors:  Igal Madar; Hayden Ravert; Barry Nelkin; Masroor Abro; Martin Pomper; Robert Dannals; James J Frost
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-05       Impact factor: 9.236

9.  Deregulation of energy metabolism promotes antifibrotic effects in human hepatic stellate cells and prevents liver fibrosis in a mouse model.

Authors:  Swathi Karthikeyan; James J Potter; Jean-Francois Geschwind; Surojit Sur; James P Hamilton; Bert Vogelstein; Kenneth W Kinzler; Esteban Mezey; Shanmugasundaram Ganapathy-Kanniappan
Journal:  Biochem Biophys Res Commun       Date:  2015-10-23       Impact factor: 3.575

Review 10.  Novel mechanisms in chemically induced hepatotoxicity.

Authors:  H M Mehendale; R A Roth; A J Gandolfi; J E Klaunig; J J Lemasters; L R Curtis
Journal:  FASEB J       Date:  1994-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.